Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2011

View Archived Issues

Phase II study assesses BAF-312 in relapsing-remitting MS

Imaging agent [123I]-BZM-055 assessed in nonhuman primates

Lostam BioPharmaceutical presents monoclonal antibodies against P. aeruginosa flagellin

Scientists in Sweden identify new biomarker for disease activity in MS

Natural plant-derived product inhibits proliferation of gastric cancer cells

Novel sterol O-acyltransferase 2 inhibitors synthesized in Japan

New HIV integrase inhibitors presented by Critical Outcome Technologies

Johnson & Johnson submits sNDA to FDA for Nucynta ER

Circadian Technologies clear to start clinical development of VGX-100

Actelion Pharmaceuticals discloses novel antibacterials

Sanofi presents new Met inhibitors

Galena Biopharma focuses on late-stage targeted cancer drug development

Piramal Life Sciences synthesizes new cytokine inhibitors

Takeda Pharmaceutical prepares novel histamine H3 receptor antagonists

TNF-Kinoid shows promise in phase IIa trial

CytRx reports further on phase Ib/II study of INNO-206

FDA approves Pacira Pharmaceuticals' Exparel

European orphan drug status for Celldex Therapeutics' rindopepimut

Takara Bio to develop gene therapy for non-Hodgkin's lymphoma

MorphoSys and Shionogi extend HuCAL research partnership

Phase II study of CK-2017357 advances

NVB-302 enters clinical testing

Infinity Pharmaceuticals begins two studies of IPI-145

FDA approves Xience Prime stent

Avanir Pharmaceuticals submits MAA for Nuedexta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...